Table 3 Association of genetically predicted age at menopause and CRC risk according to subgroups, CCFR, GECCO Consortium

From: Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer

 

N (cases/controls)

OR a

95% CI

P -value

Heterogeneity P- value b

All

5832/6285

0.99

0.95–1.03

0.56

 

Combined oestrogen–progesterone therapy

No

3266/3490

0.99

0.93–1.05

0.78

0.75

Yes

593/807

0.96

0.85–1.10

0.58

 

Oestrogen monotherapy

No

3120/3214

0.99

0.93–1.05

0.27

0.76

Yes

716/1088

1.01

0.89–1.14

0.90

 

BMI

Normal weight

2146/2665

1.00

0.93–1.07

0.97

0.50

Overweight

1866/1918

0.99

0.91–1.07

0.77

 

Obese

1284/1115

1.00

0.91–1.11

0.93

 

Underweight

74/80

0.63

0.40–0.98

0.04

 

Site

Colon

4037/6285

0.98

0.94–1.03

0.53

0.61c

Rectum

1184/6285

0.98

0.91–1.06

0.65

 
  1. BMI body mass index, CCFR Colon Cancer Family Registry, CI confidence interval, GRS genetic risk score, OR odds ratio per year
  2. aAll analyses adjusted for age, sex, study, and principal components of genetic ancestry
  3. bP-value calculated using likelihood ratio tests comparing the model with and without interaction term
  4. cP-value for heterogeneity was obtained in case-only analysis of colon vs. rectal cancer
Back to article page